This template was built with Webflow's free Prospero UI Kit. Learn more
The SCN2A gene provides instructions for making a protein called Nav1.2, a sodium channel that helps brain cells (neurons) send electrical signals. When a mutation reduces or eliminates Nav1.2 activity, researchers call that loss of function (LOF). Nav1.2 is particularly active early in brain development. When its function is reduced, the effects can ripple across multiple areas of development. If you are still building your understanding of how genetic changes work, our guide to what an SCN2A mutation is is a helpful starting point.
LOF is one of two main categories of SCN2A mutations. The other is gain of function (GOF), where the channel becomes overactive. This framework, established by Sanders et al. (2018) and Ben-Shalom et al. (2017), has shaped how clinicians approach treatment decisions. GOF mutations are typically associated with early-onset seizures (before 3 months of age). LOF mutations are more commonly linked to autism spectrum disorder (ASD) and intellectual disability. When seizures occur in children with LOF variants, they generally begin later than the early seizure patterns seen with GOF, but onset may range from infancy to later childhood, and some children never develop seizures at all (Wolff et al., 2017).
LOF variants are the most common type of disease-causing SCN2A mutation. Children with LOF variants may experience developmental delays, challenges with social communication, sensory differences, and movement difficulties. Some develop seizures in infancy or childhood. Others never do. The range is wide. That range is part of what makes the LOF category so difficult to generalize.
For families, this distinction matters. But it also raises a question many parents ask: if two children both carry LOF mutations in the same gene, why can their experiences look so different?
For years, researchers generally assumed that SCN2A nonsense mutations, one type of loss-of-function variant, would all produce the same basic result. Nonsense mutations introduce a premature stop signal in the gene's instructions. That stop signal creates a faulty copy of the gene's message (called mRNA, the working blueprint the cell uses to build protein). Loss of function can also result from other types of genetic changes, including frameshift variants, splice-site variants, gene deletions, and certain missense variants. But the Al Saneh et al. study focused specifically on nonsense mutations.
The cell has a quality-control system called nonsense-mediated decay (NMD) that detects and destroys faulty mRNA before it can be used. Whether this system catches a faulty message depends on where the premature stop signal falls within the gene. If the stop signal occurs early enough in the gene, the cell is more likely to recognize the mRNA as defective and break it down. If the stop signal falls near the very end of the gene, the cell's quality-control system often misses it, and the faulty mRNA survives (Nagy & Maquat, 1998).
Under this model, the expected outcome was simple: one working copy of the gene, half the normal protein, and a uniform state known as haploinsufficiency. The healthy copy of SCN2A still works normally. The mutated copy is silenced. The result should be the same no matter where the stop signal falls.
That logic treated all premature stop mutations as having the same effect. It was a reasonable starting assumption. But families navigating loss-of-function disorders have long observed something the model did not fully explain. Two children with LOF mutations in the same gene can present very differently from each other. One may have seizures. Another may not. One may speak. Another may be nonverbal. The label is the same. The lived experience is not.
A 2026 study published in Molecular Psychiatry by Al Saneh et al. at the University of Iowa directly tested whether two different premature stop mutations in SCN2A produce the same result in mice. They did not.
The researchers created two mouse models, each carrying a different premature stop mutation originally found in humans with SCN2A. One mutation, called Y84X, sits near the beginning of the gene. The other, R1627X, sits in the gene's final coding exon. Because the cell's quality-control system relies on landmarks that come before the final exon, Y84X should trigger mRNA decay. R1627X, positioned in the final exon, should not.
That prediction held. The cell's quality-control system partially broke down the mRNA carrying Y84X, just as expected. But the mRNA carrying R1627X was not flagged. It remained at levels matching the normal copy of the gene, meaning the surveillance system did not catch it in this experiment.
Here is where the findings get surprising. Despite this difference in mRNA handling, both mutations resulted in a comparable reduction of Nav1.2 protein. The protein outcome was similar. The effects on brain cell function overlapped in some ways but diverged in others.
Both mutations affected how brain cells produced electrical signals, but in two distinct ways. First, each individual signal rose more slowly than normal in both models. Y84X produced a larger slowdown than R1627X. Second, brain cells carrying Y84X needed a stronger push to start firing in the first place, while brain cells carrying R1627X started firing at levels closer to normal. Both mutations also reduced the number of signals brain cells produced, but only when the input was near the minimum needed to trigger firing. With stronger input, firing moved closer to normal.
The behavioral differences were equally specific. Both mouse models showed increased grooming, a behavior consistent with the repetitive patterns seen in some neurodevelopmental conditions. Baseline movement, social preference in a standard test, and startle responses to sudden sounds were preserved in both lines. But only Y84X mice showed increased exploration in a risky environment and a male-predominant difficulty with a motor learning task. R1627X mice did not show these effects.
The researchers also looked at seizures directly. In a laboratory seizure-induction (electroshock) test, both mouse lines showed no change in seizure threshold or severity compared with normal mice, and mortality during the test was actually lower. These results were reassuring within this mouse model, but they come from an artificially induced seizure test rather than the kind of spontaneous seizures seen in people, so how they translate to children with SCN2A is not yet known.
Consider what this means. Two mutations that caused a comparable loss of protein still produced distinct effects on brain cell activity and behavior in mice. Where the premature stop sat in the gene shaped whether the cell's quality-control system kicked in, and that difference was linked to the distinct outcomes, though other factors may also contribute.
The conclusion from Al Saneh et al. is clear: in these two mouse models, different premature stop mutations in the same gene were not equal. A stop near the beginning of the gene and a stop in the final coding exon produced overlapping but distinct effects. Mutation position was one factor shaping the outcome.
For parents, this research is consistent with something many have observed firsthand. Your child's experience with SCN2A loss of function may not match what you read in a general description or hear from another family. That is not because the diagnosis is wrong. It is because the biology underneath the diagnosis is more specific than a single label can capture.
Two children can both carry premature stop mutations in SCN2A. Both can have reduced Nav1.2 protein. Yet how their brain cells function and how they behave may differ based on factors including where the mutation falls within the gene. The variability families see is real, and this study offers one possible biological explanation that will need confirmation in human studies.
This does not change the diagnosis. It deepens the understanding of what the diagnosis means for each child. Your child's specific mutation, not just the broad LOF category, may be one factor shaping their individual experience. That possibility matters as the field moves toward more individualized approaches.
The Al Saneh et al. findings did not emerge in isolation. Several earlier studies using different SCN2A LOF mouse models had already revealed inconsistent results across behavioral and brain cell activity measures.
Spratt et al. (2019) found that reducing Nav1.2 weakened how brain cells in the prefrontal cortex of mice communicated with each other. A follow-up study from the same group (Spratt et al., 2021) revealed something unexpected: when Nav1.2 was completely removed from specific cortical brain cells in mature mice, those cells actually became overactive rather than underactive. Partial reduction showed subtler effects. That finding challenged the straightforward assumption that less channel function always means less brain cell activity.
Ogiwara et al. (2018) demonstrated that mice with reduced Nav1.2 developed absence-like seizures (brief episodes of staring and unresponsiveness) as adults. A subsequent study by Miyamoto et al. (2019) showed that weakened signaling between two brain regions (the cortex and the striatum) could trigger those seizures. Other groups reported mixed findings on social behavior, anxiety, and hyperactivity in mice with the same genetic change (Tatsukawa et al., 2019; Lena and Mantegazza, 2019). In some experiments, mice with one working copy of Scn2a showed social difficulties. In others, they did not.
These differences were often attributed to genetic background, testing conditions, or the age of the animals. The Al Saneh et al. study adds another variable: the position of the mutation itself.
Even when protein loss is similar, the route the cell takes to get there (whether its quality-control system caught the faulty mRNA or not) can shape what happens next in the brain.
This study reinforces a conclusion the field has been building toward. The GOF versus LOF framework, while foundational, is not the complete picture. Within the LOF category alone, mouse studies now show meaningful diversity in how different mutations affect brain cell function and behavior.
For researchers, this means that grouping all LOF mutations together in studies may hide real differences between them. More precise grouping, informed by where the mutation sits and how the cell handles the mRNA, could reveal patterns that broader analyses miss.
For clinicians, it reinforces the value of detailed genetic testing and careful review of each variant. Treatment approaches may eventually need to account for mutation-specific biology, not just the broad GOF or LOF label. This research strengthens the scientific case for moving in that direction.
For families, it offers a scientific basis for what many already sense: your child is not a category. They are an individual. Their specific mutation may play a role in shaping their experience in ways the field is only beginning to map.
The path forward depends on building the evidence base to support that kind of precision. Registries, natural history studies, and participation in SCN2A research all contribute to the detailed, mutation-by-mutation understanding this study calls for. Every family that participates adds to the data that will make individualized approaches possible.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. You can help build the evidence base by joining the SCN2A patient registry, put your family on the map by joining the SCN2A WorldMap, and help fund the research that moves us all forward by making a donation.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
1. Al Saneh A, et al. Nonsense-mediated decay influences position-dependent effects of SCN2A premature stop codons on neuronal excitability and behavior. Molecular Psychiatry. 2026. DOI: 10.1038/s41380-026-03723-z
2. Sanders SJ, et al. Progress in understanding and treating SCN2A-mediated disorders. Trends in Neurosciences. 2018;41(7):442-456.
3. Ben-Shalom R, et al. Opposing effects on NaV1.2 function underlie differences between SCN2A variants. Biological Psychiatry. 2017;82(3):224-232.
4. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes. Trends in Biochemical Sciences. 1998;23:198-199.
5. Spratt PWE, et al. The autism-associated gene Scn2a contributes to dendritic excitability and synaptic function. Neuron. 2019;103(4):673-685.
6. Spratt PWE, et al. Paradoxical hyperexcitability from NaV1.2 sodium channel loss. Cell Reports. 2021;36(5):109483.
7. Ogiwara I, et al. Nav1.2 haplodeficiency in excitatory neurons causes absence-like seizures. Communications Biology. 2018;1:96.
8. Miyamoto H, et al. Impaired cortico-striatal excitatory transmission triggers epilepsy. Nature Communications. 2019;10:1917.
9. Tatsukawa T, et al. Scn2a haploinsufficient mice display a spectrum of phenotypes. Molecular Autism. 2019;10:15.
10. Lena I, Mantegazza M. NaV1.2 haploinsufficiency in Scn2a knock-out mice. Scientific Reports. 2019;9:12886.
11. Wolff M, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017;140(5):1316-1336.
Share
The SCN2A gene provides instructions for making a protein called Nav1.2, a sodium channel that helps brain cells (neurons) send electrical signals. When a mutation reduces or eliminates Nav1.2 activity, researchers call that loss of function (LOF). Nav1.2 is particularly active early in brain development. When its function is reduced, the effects can ripple across multiple areas of development. If you are still building your understanding of how genetic changes work, our guide to what an SCN2A mutation is is a helpful starting point.
LOF is one of two main categories of SCN2A mutations. The other is gain of function (GOF), where the channel becomes overactive. This framework, established by Sanders et al. (2018) and Ben-Shalom et al. (2017), has shaped how clinicians approach treatment decisions. GOF mutations are typically associated with early-onset seizures (before 3 months of age). LOF mutations are more commonly linked to autism spectrum disorder (ASD) and intellectual disability. When seizures occur in children with LOF variants, they generally begin later than the early seizure patterns seen with GOF, but onset may range from infancy to later childhood, and some children never develop seizures at all (Wolff et al., 2017).
LOF variants are the most common type of disease-causing SCN2A mutation. Children with LOF variants may experience developmental delays, challenges with social communication, sensory differences, and movement difficulties. Some develop seizures in infancy or childhood. Others never do. The range is wide. That range is part of what makes the LOF category so difficult to generalize.
For families, this distinction matters. But it also raises a question many parents ask: if two children both carry LOF mutations in the same gene, why can their experiences look so different?
For years, researchers generally assumed that SCN2A nonsense mutations, one type of loss-of-function variant, would all produce the same basic result. Nonsense mutations introduce a premature stop signal in the gene's instructions. That stop signal creates a faulty copy of the gene's message (called mRNA, the working blueprint the cell uses to build protein). Loss of function can also result from other types of genetic changes, including frameshift variants, splice-site variants, gene deletions, and certain missense variants. But the Al Saneh et al. study focused specifically on nonsense mutations.
The cell has a quality-control system called nonsense-mediated decay (NMD) that detects and destroys faulty mRNA before it can be used. Whether this system catches a faulty message depends on where the premature stop signal falls within the gene. If the stop signal occurs early enough in the gene, the cell is more likely to recognize the mRNA as defective and break it down. If the stop signal falls near the very end of the gene, the cell's quality-control system often misses it, and the faulty mRNA survives (Nagy & Maquat, 1998).
Under this model, the expected outcome was simple: one working copy of the gene, half the normal protein, and a uniform state known as haploinsufficiency. The healthy copy of SCN2A still works normally. The mutated copy is silenced. The result should be the same no matter where the stop signal falls.
That logic treated all premature stop mutations as having the same effect. It was a reasonable starting assumption. But families navigating loss-of-function disorders have long observed something the model did not fully explain. Two children with LOF mutations in the same gene can present very differently from each other. One may have seizures. Another may not. One may speak. Another may be nonverbal. The label is the same. The lived experience is not.
A 2026 study published in Molecular Psychiatry by Al Saneh et al. at the University of Iowa directly tested whether two different premature stop mutations in SCN2A produce the same result in mice. They did not.
The researchers created two mouse models, each carrying a different premature stop mutation originally found in humans with SCN2A. One mutation, called Y84X, sits near the beginning of the gene. The other, R1627X, sits in the gene's final coding exon. Because the cell's quality-control system relies on landmarks that come before the final exon, Y84X should trigger mRNA decay. R1627X, positioned in the final exon, should not.
That prediction held. The cell's quality-control system partially broke down the mRNA carrying Y84X, just as expected. But the mRNA carrying R1627X was not flagged. It remained at levels matching the normal copy of the gene, meaning the surveillance system did not catch it in this experiment.
Here is where the findings get surprising. Despite this difference in mRNA handling, both mutations resulted in a comparable reduction of Nav1.2 protein. The protein outcome was similar. The effects on brain cell function overlapped in some ways but diverged in others.
Both mutations affected how brain cells produced electrical signals, but in two distinct ways. First, each individual signal rose more slowly than normal in both models. Y84X produced a larger slowdown than R1627X. Second, brain cells carrying Y84X needed a stronger push to start firing in the first place, while brain cells carrying R1627X started firing at levels closer to normal. Both mutations also reduced the number of signals brain cells produced, but only when the input was near the minimum needed to trigger firing. With stronger input, firing moved closer to normal.
The behavioral differences were equally specific. Both mouse models showed increased grooming, a behavior consistent with the repetitive patterns seen in some neurodevelopmental conditions. Baseline movement, social preference in a standard test, and startle responses to sudden sounds were preserved in both lines. But only Y84X mice showed increased exploration in a risky environment and a male-predominant difficulty with a motor learning task. R1627X mice did not show these effects.
The researchers also looked at seizures directly. In a laboratory seizure-induction (electroshock) test, both mouse lines showed no change in seizure threshold or severity compared with normal mice, and mortality during the test was actually lower. These results were reassuring within this mouse model, but they come from an artificially induced seizure test rather than the kind of spontaneous seizures seen in people, so how they translate to children with SCN2A is not yet known.
Consider what this means. Two mutations that caused a comparable loss of protein still produced distinct effects on brain cell activity and behavior in mice. Where the premature stop sat in the gene shaped whether the cell's quality-control system kicked in, and that difference was linked to the distinct outcomes, though other factors may also contribute.
The conclusion from Al Saneh et al. is clear: in these two mouse models, different premature stop mutations in the same gene were not equal. A stop near the beginning of the gene and a stop in the final coding exon produced overlapping but distinct effects. Mutation position was one factor shaping the outcome.
For parents, this research is consistent with something many have observed firsthand. Your child's experience with SCN2A loss of function may not match what you read in a general description or hear from another family. That is not because the diagnosis is wrong. It is because the biology underneath the diagnosis is more specific than a single label can capture.
Two children can both carry premature stop mutations in SCN2A. Both can have reduced Nav1.2 protein. Yet how their brain cells function and how they behave may differ based on factors including where the mutation falls within the gene. The variability families see is real, and this study offers one possible biological explanation that will need confirmation in human studies.
This does not change the diagnosis. It deepens the understanding of what the diagnosis means for each child. Your child's specific mutation, not just the broad LOF category, may be one factor shaping their individual experience. That possibility matters as the field moves toward more individualized approaches.
The Al Saneh et al. findings did not emerge in isolation. Several earlier studies using different SCN2A LOF mouse models had already revealed inconsistent results across behavioral and brain cell activity measures.
Spratt et al. (2019) found that reducing Nav1.2 weakened how brain cells in the prefrontal cortex of mice communicated with each other. A follow-up study from the same group (Spratt et al., 2021) revealed something unexpected: when Nav1.2 was completely removed from specific cortical brain cells in mature mice, those cells actually became overactive rather than underactive. Partial reduction showed subtler effects. That finding challenged the straightforward assumption that less channel function always means less brain cell activity.
Ogiwara et al. (2018) demonstrated that mice with reduced Nav1.2 developed absence-like seizures (brief episodes of staring and unresponsiveness) as adults. A subsequent study by Miyamoto et al. (2019) showed that weakened signaling between two brain regions (the cortex and the striatum) could trigger those seizures. Other groups reported mixed findings on social behavior, anxiety, and hyperactivity in mice with the same genetic change (Tatsukawa et al., 2019; Lena and Mantegazza, 2019). In some experiments, mice with one working copy of Scn2a showed social difficulties. In others, they did not.
These differences were often attributed to genetic background, testing conditions, or the age of the animals. The Al Saneh et al. study adds another variable: the position of the mutation itself.
Even when protein loss is similar, the route the cell takes to get there (whether its quality-control system caught the faulty mRNA or not) can shape what happens next in the brain.
This study reinforces a conclusion the field has been building toward. The GOF versus LOF framework, while foundational, is not the complete picture. Within the LOF category alone, mouse studies now show meaningful diversity in how different mutations affect brain cell function and behavior.
For researchers, this means that grouping all LOF mutations together in studies may hide real differences between them. More precise grouping, informed by where the mutation sits and how the cell handles the mRNA, could reveal patterns that broader analyses miss.
For clinicians, it reinforces the value of detailed genetic testing and careful review of each variant. Treatment approaches may eventually need to account for mutation-specific biology, not just the broad GOF or LOF label. This research strengthens the scientific case for moving in that direction.
For families, it offers a scientific basis for what many already sense: your child is not a category. They are an individual. Their specific mutation may play a role in shaping their experience in ways the field is only beginning to map.
The path forward depends on building the evidence base to support that kind of precision. Registries, natural history studies, and participation in SCN2A research all contribute to the detailed, mutation-by-mutation understanding this study calls for. Every family that participates adds to the data that will make individualized approaches possible.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. You can help build the evidence base by joining the SCN2A patient registry, put your family on the map by joining the SCN2A WorldMap, and help fund the research that moves us all forward by making a donation.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
1. Al Saneh A, et al. Nonsense-mediated decay influences position-dependent effects of SCN2A premature stop codons on neuronal excitability and behavior. Molecular Psychiatry. 2026. DOI: 10.1038/s41380-026-03723-z
2. Sanders SJ, et al. Progress in understanding and treating SCN2A-mediated disorders. Trends in Neurosciences. 2018;41(7):442-456.
3. Ben-Shalom R, et al. Opposing effects on NaV1.2 function underlie differences between SCN2A variants. Biological Psychiatry. 2017;82(3):224-232.
4. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes. Trends in Biochemical Sciences. 1998;23:198-199.
5. Spratt PWE, et al. The autism-associated gene Scn2a contributes to dendritic excitability and synaptic function. Neuron. 2019;103(4):673-685.
6. Spratt PWE, et al. Paradoxical hyperexcitability from NaV1.2 sodium channel loss. Cell Reports. 2021;36(5):109483.
7. Ogiwara I, et al. Nav1.2 haplodeficiency in excitatory neurons causes absence-like seizures. Communications Biology. 2018;1:96.
8. Miyamoto H, et al. Impaired cortico-striatal excitatory transmission triggers epilepsy. Nature Communications. 2019;10:1917.
9. Tatsukawa T, et al. Scn2a haploinsufficient mice display a spectrum of phenotypes. Molecular Autism. 2019;10:15.
10. Lena I, Mantegazza M. NaV1.2 haploinsufficiency in Scn2a knock-out mice. Scientific Reports. 2019;9:12886.
11. Wolff M, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017;140(5):1316-1336.
Vlad Magdalin
Accelerating research and treatment for SCN2A-related disorders.
Get the latest SCN2A research and community news.